Stanford University 
Welcome,         Profile    Billing    Logout  
 7 Products   33 Diseases  7 Products   15 Trials   1116 News 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
NCT04967430: TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Active, not recruiting
3
763
Canada
Peginterferon Lambda-1A, Placebo
University Health Network, Toronto
Sars-CoV2, Covid19
03/22
06/22
2021-003665-35: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

Not yet recruiting
3
150
Europe, RoW
Pegylated Interferon Lambda-1a, 361529, Solution for injection/infusion in pre-filled syringe
Eiger BioPharmaceuticals, Inc., EIGER BIOPHARMACEUTICALS, INC., Eiger BioPharmaceuticals, Inc.
Chronic Hepatitis Delta Virus (HDV) Infection, Chronic Hepatitis Delta Virus (HDV) Infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT04727424: Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Recruiting
3
7819
RoW
Spirulin Platensis, Budesonide Powder, Fluvoxamine Maleate 100 MG [Luvox], Fluoxetine 20 MG, Budesonide powder, Placebo
Cardresearch, Cytel Inc., McMaster University, Fastgrants, Eiger BioPharmaceuticals, RainWater Foundation
Covid19, SARS-Associated Coronavirus
06/24
07/24
LIMT-2, NCT05070364 / 2021-003665-35: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc.
Hepatitis Delta Virus
06/24
01/25
Eiger BioPharmaceuti: Peginterferon Lambda in COVID-19

Not yet recruiting
2
0
US
peginterferon lambda-1a (BMS-914143) - BMS, Eiger
BMS, Eiger BioPharm
Mild COVID-19
 
 
ILIAD, NCT04354259: Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19

Completed
2
157
Canada, RoW
Peginterferon Lambda-1A, placebo
University Health Network, Toronto, Michael Garron Hospital
Sars-CoV2, Covid-19
08/22
12/22
NCT04534673: Pegylated Interferon Lambda for Treatment of COVID-19 Infection

Active, not recruiting
2
40
RoW
Lambda 180 mcg S.C, Lambda
Soroka University Medical Center
COVID-19
12/23
12/24
Zevaskyn (prademagene zamikeracel) / Abeona Therap
VITAL, NCT03632265: Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Not yet recruiting
3
15
NA
EB-101, LEAES: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Jean Yuh Tang, Abeona Therapeutics, Inc
Recessive Dystrophic Epidermolysis Bullosa
09/20
03/21
NCT05725018: A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Active, not recruiting
3
12
US
EB-101 Surgical application of RDEB wounds, pz-cel
Abeona Therapeutics, Inc
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
09/25
09/25
NCT01263379: Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Completed
1/2
12
US
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets, LEAES
Abeona Therapeutics, Inc, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Stanford University
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
03/22
03/22
NCT05708677: A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

Enrolling by invitation
N/A
22
US
EB-101, pz-cel
Abeona Therapeutics, Inc
RDEB
02/36
08/36
VK-2019 / The Wistar Institute, Stanford University
NCT04925544: Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Recruiting
2
61
US
VK-2019
Stanford University, National Institutes of Health (NIH), National Cancer Institute (NCI)
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma
02/28
02/31
NCT06420349: NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800, CCT 361814, CCT-361814, CCT361814, HSF1 Pathway Inhibitor NXP800, NXP-800, NXP800, VK2019, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Ultrasound-Guided Biopsy, Ultrasound Biopsy, Ultrasound Guided Biopsy
Mayo Clinic
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
05/26
05/26
NCT06789159: A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Recruiting
1
30
US
VK-2019
Thomas Jefferson University, National Cancer Institute (NCI), The Wistar Institute
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed, Epstein-Barr Virus (EBV) Infection
10/28
10/28
firicabtagene autoleucel (CRG-022) / CARGO Therap
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Terminated
2
101
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
04/25
04/25
IRB-50836, NCT04088890: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Completed
1
52
US
Fludarabine, Cyclophosphamide, CD22 CAR
Stanford University, National Cancer Institute (NCI), The Leukemia and Lymphoma Society, American Society of Hematology
B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
11/24
03/25
NCT06408194: Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Recruiting
1
20
US
CD22CART infusion, Tisagenlecleucel, KYMRIAH
Stanford University
Leukemia, Acute Lymphoblastic Leukemia
11/25
11/25
NCT04088864: CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Active, not recruiting
1
10
US
Fludarabine, Cyclophosphamide, Autologous CD22 CAR T
Stanford University
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
10/23
09/36
ASC930 / ASC Therapeutics, City of Hope, Karolinska Institute, Stanford University
NCT04883918: ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Not yet recruiting
2
60
NA
ASC930
ASC Therapeutics
Acute-graft-versus-host Disease
01/26
04/26
GD2-CART / Stanford University
NCT04196413: GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

Recruiting
1
54
US
GD2 CAR T cells, Fludarabine, Cyclophosphamide
Crystal Mackall, MD, California Institute for Regenerative Medicine (CIRM), CureSearch, National Institutes of Health (NIH)
Glioma of Spinal Cord, Glioma of Brainstem
07/28
07/43
B7H3-CAR T / Stanford University
NCT05474378: B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

Recruiting
1
39
US
B7-H3CART, B7H3-CAR T
Crystal Mackall, MD, California Institute for Regenerative Medicine (CIRM)
Brain and Nervous System
08/25
08/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
NCT04967430: TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Active, not recruiting
3
763
Canada
Peginterferon Lambda-1A, Placebo
University Health Network, Toronto
Sars-CoV2, Covid19
03/22
06/22
2021-003665-35: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

Not yet recruiting
3
150
Europe, RoW
Pegylated Interferon Lambda-1a, 361529, Solution for injection/infusion in pre-filled syringe
Eiger BioPharmaceuticals, Inc., EIGER BIOPHARMACEUTICALS, INC., Eiger BioPharmaceuticals, Inc.
Chronic Hepatitis Delta Virus (HDV) Infection, Chronic Hepatitis Delta Virus (HDV) Infection, Diseases [C] - Virus Diseases [C02]
 
 
NCT04727424: Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Recruiting
3
7819
RoW
Spirulin Platensis, Budesonide Powder, Fluvoxamine Maleate 100 MG [Luvox], Fluoxetine 20 MG, Budesonide powder, Placebo
Cardresearch, Cytel Inc., McMaster University, Fastgrants, Eiger BioPharmaceuticals, RainWater Foundation
Covid19, SARS-Associated Coronavirus
06/24
07/24
LIMT-2, NCT05070364 / 2021-003665-35: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc.
Hepatitis Delta Virus
06/24
01/25
Eiger BioPharmaceuti: Peginterferon Lambda in COVID-19

Not yet recruiting
2
0
US
peginterferon lambda-1a (BMS-914143) - BMS, Eiger
BMS, Eiger BioPharm
Mild COVID-19
 
 
ILIAD, NCT04354259: Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19

Completed
2
157
Canada, RoW
Peginterferon Lambda-1A, placebo
University Health Network, Toronto, Michael Garron Hospital
Sars-CoV2, Covid-19
08/22
12/22
NCT04534673: Pegylated Interferon Lambda for Treatment of COVID-19 Infection

Active, not recruiting
2
40
RoW
Lambda 180 mcg S.C, Lambda
Soroka University Medical Center
COVID-19
12/23
12/24
Zevaskyn (prademagene zamikeracel) / Abeona Therap
VITAL, NCT03632265: Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Not yet recruiting
3
15
NA
EB-101, LEAES: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Jean Yuh Tang, Abeona Therapeutics, Inc
Recessive Dystrophic Epidermolysis Bullosa
09/20
03/21
NCT05725018: A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Active, not recruiting
3
12
US
EB-101 Surgical application of RDEB wounds, pz-cel
Abeona Therapeutics, Inc
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
09/25
09/25
NCT01263379: Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

Completed
1/2
12
US
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets, LEAES
Abeona Therapeutics, Inc, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Stanford University
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
03/22
03/22
NCT05708677: A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

Enrolling by invitation
N/A
22
US
EB-101, pz-cel
Abeona Therapeutics, Inc
RDEB
02/36
08/36
VK-2019 / The Wistar Institute, Stanford University
NCT04925544: Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Recruiting
2
61
US
VK-2019
Stanford University, National Institutes of Health (NIH), National Cancer Institute (NCI)
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma
02/28
02/31
NCT06420349: NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Recruiting
1
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800, CCT 361814, CCT-361814, CCT361814, HSF1 Pathway Inhibitor NXP800, NXP-800, NXP800, VK2019, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Ultrasound-Guided Biopsy, Ultrasound Biopsy, Ultrasound Guided Biopsy
Mayo Clinic
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
05/26
05/26
NCT06789159: A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Recruiting
1
30
US
VK-2019
Thomas Jefferson University, National Cancer Institute (NCI), The Wistar Institute
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed, Epstein-Barr Virus (EBV) Infection
10/28
10/28
firicabtagene autoleucel (CRG-022) / CARGO Therap
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Terminated
2
101
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
04/25
04/25
IRB-50836, NCT04088890: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Completed
1
52
US
Fludarabine, Cyclophosphamide, CD22 CAR
Stanford University, National Cancer Institute (NCI), The Leukemia and Lymphoma Society, American Society of Hematology
B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
11/24
03/25
NCT06408194: Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Recruiting
1
20
US
CD22CART infusion, Tisagenlecleucel, KYMRIAH
Stanford University
Leukemia, Acute Lymphoblastic Leukemia
11/25
11/25
NCT04088864: CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Active, not recruiting
1
10
US
Fludarabine, Cyclophosphamide, Autologous CD22 CAR T
Stanford University
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
10/23
09/36
ASC930 / ASC Therapeutics, City of Hope, Karolinska Institute, Stanford University
NCT04883918: ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Not yet recruiting
2
60
NA
ASC930
ASC Therapeutics
Acute-graft-versus-host Disease
01/26
04/26
GD2-CART / Stanford University
NCT04196413: GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

Recruiting
1
54
US
GD2 CAR T cells, Fludarabine, Cyclophosphamide
Crystal Mackall, MD, California Institute for Regenerative Medicine (CIRM), CureSearch, National Institutes of Health (NIH)
Glioma of Spinal Cord, Glioma of Brainstem
07/28
07/43
B7H3-CAR T / Stanford University
NCT05474378: B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

Recruiting
1
39
US
B7-H3CART, B7H3-CAR T
Crystal Mackall, MD, California Institute for Regenerative Medicine (CIRM)
Brain and Nervous System
08/25
08/25

Download Options